Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR
Abstract Background Using a Symmetry C18 (4.6 × 150 mm, 3.5) column, a high-performance liquid chromatographic method for quantification of Rilpivirine and Cabotegravir in active pharmaceutical ingredients was developed and validated. The mobile phase is made up of buffer, acetonitrile, and 0.1 perc...
Guardado en:
Autores principales: | Anuradha Vejendla, Subrahmanyam Talari, Raju Moturu, S. N. Murthy Boddapati, A. Emmanuel Kola |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SpringerOpen
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bb740d18053343ea90a656ec5ff22414 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers E, et al.
Publicado: (2018) -
The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
por: Mehta R, et al.
Publicado: (2020) -
Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
por: Z. C. Lim, et al.
Publicado: (2021) -
Characterization of novel stress degradation products of Bempedoic acid and Ezetimibe using UPLC–MS/MS: development and validation of stability-indicating UPLC method
por: Anuradha Vejendla, et al.
Publicado: (2021) -
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez C, et al.
Publicado: (2019)